What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Cora N. Sternberg mostly deals with Internal medicine, Surgery, Oncology, Prostate cancer and Urology.
Within one scientific family, Cora N. Sternberg focuses on topics pertaining to Gastroenterology under Internal medicine, and may sometimes address concerns connected to Neutropenia and Mucositis.
Her Surgery study incorporates themes from Transitional cell carcinoma, Carcinoma and Hazard ratio.
Her work on Renal cell carcinoma is typically connected to Context as part of general Oncology study, connecting several disciplines of science.
She studied Prostate cancer and Docetaxel that intersect with Prednisone, Cancer biomarkers, Chemotherapy regimen, Satraplatin and Endocrinology.
Her Urology research is multidisciplinary, incorporating perspectives in Abiraterone acetate, Palliative care and Performance status.
Her most cited work include:
- Abiraterone and Increased Survival in Metastatic Prostate Cancer (3178 citations)
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy (3043 citations)
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial (1927 citations)
What are the main themes of her work throughout her whole career to date?
Cora N. Sternberg mainly focuses on Internal medicine, Oncology, Prostate cancer, Chemotherapy and Surgery.
Her study in the fields of Docetaxel, Enzalutamide, Clinical trial and Renal cell carcinoma under the domain of Internal medicine overlaps with other disciplines such as In patient.
Her Oncology research includes elements of Bladder cancer, Cancer, Phases of clinical research and Hazard ratio.
The Chemotherapy study combines topics in areas such as Gastroenterology and Regimen.
Her Surgery research includes themes of Transitional cell carcinoma, Carcinoma and Urology.
Her Cisplatin study deals with Vinblastine intersecting with Methotrexate.
She most often published in these fields:
- Internal medicine (73.40%)
- Oncology (62.92%)
- Prostate cancer (33.63%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (73.40%)
- Oncology (62.92%)
- Prostate cancer (33.63%)
In recent papers she was focusing on the following fields of study:
Cora N. Sternberg focuses on Internal medicine, Oncology, Prostate cancer, Castration resistant and Enzalutamide.
Her study in Docetaxel, Atezolizumab, Cancer, Hazard ratio and Clinical trial falls within the category of Internal medicine.
Her Oncology research is multidisciplinary, incorporating perspectives in Pembrolizumab, Metastatic Urothelial Carcinoma, Chemotherapy and Bladder cancer.
Her studies in Chemotherapy integrate themes in fields like Avelumab and Regimen.
Cora N. Sternberg usually deals with Prostate cancer and limits it to topics linked to Cancer research and Antibody and Sacituzumab govitecan.
Her Enzalutamide study integrates concerns from other disciplines, such as Progression-free survival, Randomized controlled trial, Androgen deprivation therapy, Prostate-specific antigen and Double blind.
Between 2018 and 2021, her most popular works were:
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. (193 citations)
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer (175 citations)
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma (151 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Cora N. Sternberg mainly investigates Internal medicine, Oncology, Prostate cancer, Enzalutamide and Castration resistant.
Her Oncology study combines topics in areas such as Pembrolizumab, Avelumab, Cancer and Chemotherapy.
Her Chemotherapy research integrates issues from Bladder cancer, Metastatic Urothelial Carcinoma, Interim analysis and Regimen.
Her study in Prostate cancer is interdisciplinary in nature, drawing from both Cancer research, Retrospective cohort study, Overall survival and Consensus conference.
Her Enzalutamide study incorporates themes from Prostate-specific antigen and Hazard ratio.
Her Proportional hazards model study contributes to a more complete understanding of Surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
